Stroke RSS Page 17

Filtered By:
Condition: Hypertension
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 256 results found since Jan 2013.

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
CONCLUSION: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients. PMID: 30554492 [PubMed - in process]
Source: Yonsei Medical Journal - December 18, 2018 Category: Universities & Medical Training Authors: Kim KE, Yang PS, Jang E, Kim S, Joung B Tags: Yonsei Med J Source Type: research

Strategies for Reversal of Warfarin Following Acute Bleed
A patient with altered mental status presents via EMS after being found by family. She has a medical history significant for hypertension, diabetes, and atrial fibrillation for which she receives oral anticoagulation for stroke prevention. After the initial workup comes back negative, a computed tomographic scan of the brain is performed and the patient is found to have a large intraparenchymal hemorrhage that extends into the ventricles.
Source: Journal of Emergency Nursing: JEN - April 30, 2019 Category: Nursing Authors: Brian W. Gilbert, Tessa Reynolds, Joel B. Huffman, Katherine Hall Tags: Pharm/Tox Corner Source Type: research

Factors Affecting Prognosis in Patients With Spontaneous Supratentorial Intracerebral Hemorrhage Under Medical and Surgical Treatment
Spontaneous intracerebral hemorrhage (ICH) is a vascular brain disease that causes very high rates of death and disability. Whether surgical or medical treatment is more appropriate is controversial. The purpose of the study was to examine the morbidity and mortality rates of surgical and medical therapy and their differences in order to determine which patients should be operated. In our study, the authors selected randomly and evaluated retrospectively 49 patients who were operated in Haydarpaşa Numune Research and Education Hospital Neurosurgery Clinic and 51 patients who received medical therapy at Neurology Clinic ...
Source: Journal of Craniofacial Surgery - October 1, 2019 Category: Surgery Tags: Brief Clinical Studies Source Type: research

Elderly female with CHF complains of abdominal pain, nausea and vomiting, dizziness, and confusion for 5 days. What is the cause?
Author: V. Dimov, M.D.Reviewer: S. Randhawa, M.D.A 96-year-old African American female (AAF) was admitted from a nursing home with complaints of abdominal pain, nausea and vomiting (N/V), dizziness, confusion and double vision for 5 days. She was discharged from the hospital just 4 days ago. Digoxin was started during that previous hospitalization for control of tachycardia in atrial fibrillation. One day prior to discharge, digoxin level was 1.8 mg/mL and digoxin dose was decreased to 125 mcg PO Q 48 hr.Past medical history (PMH)Hypertension, atrial fibrillation, coronary artery disease, stroke, congestive heart failure.M...
Source: Clinical Cases and Images - August 2, 2009 Category: General Medicine Tags: Cardiology Intensive Care Toxicology Source Type: news

A randomized comparison of two direct oral anticoagulants for patients undergoing cardiac ablation with a contemporary warfarin control arm
ConclusionsThe incidence of asymptomatic cerebral micro-thromboembolism and hemopericardium in AF ablation was similar among patients using edoxaban, rivaroxaban, and warfarin. However, low doses of DOACs may increase the risk of asymptomatic stroke.
Source: Journal of Interventional Cardiac Electrophysiology - April 20, 2020 Category: Cardiology Source Type: research

Antithrombotics in intracerebral hemorrhage in the era of novel agents and antidotes: A review.
CONCLUSION: Antithrombotic therapy is of great importance when indicated, though it does not come without crucial side-effects, such as ICH. Optimal timing of withdrawal, reversal, and resumption of antithrombotic treatment should be determined by a multidisciplinary team consisting of a stroke specialist, a cardiologist, and a neurosurgeon, who will individually approach the needs and risks of each patient. PMID: 32320168 [PubMed - in process]
Source: Journal of Population Therapeutics and Clinical Pharmacology - April 24, 2020 Category: Drugs & Pharmacology Tags: J Popul Ther Clin Pharmacol Source Type: research

Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices
ConclusionsFactor Xa inhibitors may be viable treatment options for CF-LVAD patients for whom warfarin therapy has failed. Large prospective studies are necessary to confirm these results.
Source: General Thoracic and Cardiovascular Surgery - April 26, 2020 Category: Cardiovascular & Thoracic Surgery Source Type: research

Rationale, Design, and Baseline Characteristics of the BioProsthetic Valves with Atrial Fibrillation (BPV-AF) Study
ConclusionPatients enrolled into this study are typical of the wider Japanese AF/BPV population in terms of age and clinical history. Future data accruing from the observational period will contribute to future treatment recommendations and guide therapeutic decisions in patients with BPV and AF.Trial registrationClinicalTrials.gov Identifier: UMIN000034485
Source: Cardiovascular Drugs and Therapy - July 23, 2020 Category: Cardiology Source Type: research

Comparison of effects of triple antithrombotic therapy and dual antiplatelet therapy on long-term outcomes of acute myocardial infarction
This study aimed to compare the long-term outcome of triple antithrombotic therapy (TAT) with that of dual antiplatelet therapy (DAPT) after AMI. This was a nationwide, propensity score-matched, case –control study of 186,112 first AMI patients, of whom 2,825 received TAT comprising aspirin, clopidogrel, and warfarin. Propensity score matching in a ratio of 1:4 by age, sex, comorbidities, and treatment was adopted, Finally, 2,813 AMI patients and 11,252 matched controls that were administered TAT and DAPT (aspirin and clopidogrel), respectively, were included in our analysis. The 12-year overall survival rate did not dif...
Source: Heart and Vessels - October 8, 2020 Category: Cardiology Source Type: research

Risks and benefits of concurrent treatment with antiplatelet and anticoagulation therapy in post ‐op bioprosthetic aortic valve replacement patients
ConclusionPatients who underwent bAVR and were discharged on concurrent therapy compared to aspirin only had a significantly increased risk of bleeding without a significant difference in thromboembolic events.
Source: Journal of Cardiac Surgery - January 13, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Carma Yaghi, Rajeev Masson, Kyoko Yamada, Shiyun Zhu, Christine Fong, Aida Shirazi, Paul LaPunzina, Kenny Mok Tags: ORIGINAL ARTICLE Source Type: research

Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study
ConclusionAdherence to oral anticoagulants is suboptimal. Interventions tailored according to past adherence trajectories may be effective in improving patient ’s adherence.
Source: International Journal of Clinical Pharmacy - July 1, 2022 Category: Drugs & Pharmacology Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18